{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T11:04:07Z","timestamp":1787828647852,"version":"build-2784847793"},"reference-count":38,"publisher":"American Medical Association (AMA)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Dermatol"],"published-print":{"date-parts":[[2019,3,1]]},"DOI":"10.1001\/jamadermatol.2018.4940","type":"journal-article","created":{"date-parts":[[2019,1,2]],"date-time":"2019-01-02T12:19:33Z","timestamp":1546431573000},"page":"361","source":"Crossref","is-referenced-by-count":137,"title":["Imatinib Treatment for Locally Advanced or Metastatic Dermatofibrosarcoma Protuberans"],"prefix":"10.1001","volume":"155","author":[{"given":"Cristian","family":"Navarrete-Dechent","sequence":"first","affiliation":[{"name":"Department of Dermatology, Facultad de Medicina, Pontificia Universidad Cat\u00f3lica de Chile, Santiago, Chile"},{"name":"Dermatology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shoko","family":"Mori","sequence":"additional","affiliation":[{"name":"Dermatology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher A.","family":"Barker","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark A.","family":"Dickson","sequence":"additional","affiliation":[{"name":"Sarcoma Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kishwer S.","family":"Nehal","sequence":"additional","affiliation":[{"name":"Dermatology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"6","key":"drv180006r1","doi-asserted-by":"publisher","first-page":"968","DOI":"10.1016\/j.jaad.2006.09.006","article-title":"Descriptive epidemiology of dermatofibrosarcoma protuberans in the United States, 1973 to 2002.","volume":"56","author":"Criscione","year":"2007","journal-title":"J Am Acad Dermatol"},{"issue":"11","key":"drv180006r2","doi-asserted-by":"publisher","first-page":"2503","DOI":"10.1002\/(ISSN)1097-0142","article-title":"Dermatofibrosarcoma protuberans.","volume":"101","author":"Mendenhall","year":"2004","journal-title":"Cancer"},{"issue":"12","key":"drv180006r3","doi-asserted-by":"publisher","first-page":"2711","DOI":"10.1002\/(ISSN)1097-0142","article-title":"Dermatofibrosarcoma protuberans: a clinicopathologic analysis of patients treated and followed at a single institution.","volume":"88","author":"Bowne","year":"2000","journal-title":"Cancer"},{"issue":"9","key":"drv180006r4","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1007\/s11864-017-0498-5","article-title":"Dermatofibrosarcoma protuberans.","volume":"18","author":"Acosta","year":"2017","journal-title":"Curr Treat Options Oncol"},{"key":"drv180006r5","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/j.anndiagpath.2016.09.013","article-title":"Dermatofibrosarcoma protuberans: pathology, genetics, and potential therapeutic strategies.","volume":"25","author":"Thway","year":"2016","journal-title":"Ann Diagn Pathol"},{"key":"drv180006r6","doi-asserted-by":"publisher","first-page":"S24","DOI":"10.1097\/DSS.0000000000000300","article-title":"Incidence and survival of primary dermatofibrosarcoma protuberans in the United States.","volume":"42","author":"Kreicher","year":"2016","journal-title":"Dermatol Surg"},{"issue":"5","key":"drv180006r7","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1097\/00000478-199805000-00009","article-title":"Fibrosarcomatous (\u201chigh-grade\u201d) dermatofibrosarcoma protuberans: clinicopathologic and immunohistochemical study of a series of 41 cases with emphasis on prognostic significance.","volume":"22","author":"Mentzel","year":"1998","journal-title":"Am J Surg Pathol"},{"issue":"12","key":"drv180006r8","doi-asserted-by":"publisher","first-page":"1365","DOI":"10.1001\/jamadermatol.2016.1886","article-title":"Prognostic factors, treatment, and survival in dermatofibrosarcoma protuberans.","volume":"152","author":"Criscito","year":"2016","journal-title":"JAMA Dermatol"},{"issue":"6","key":"drv180006r9","doi-asserted-by":"publisher","first-page":"1134","DOI":"10.1016\/j.ejso.2017.03.011","article-title":"Long-term results of treatment of advanced dermatofibrosarcoma protuberans (DFSP) with imatinib mesylate: the impact of fibrosarcomatous transformation.","volume":"43","author":"Rutkowski","year":"2017","journal-title":"Eur J Surg Oncol"},{"issue":"2","key":"drv180006r10","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1245\/s10434-010-1316-5","article-title":"Dermatofibrosarcoma protuberans (DFSP): predictors of recurrence and the use of systemic therapy.","volume":"18","author":"Fields","year":"2011","journal-title":"Ann Surg Oncol"},{"issue":"8","key":"drv180006r11","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1586\/14737140.2015.1052799","article-title":"Current treatment options for dermatofibrosarcoma protuberans.","volume":"15","author":"Rutkowski","year":"2015","journal-title":"Expert Rev Anticancer Ther"},{"issue":"1","key":"drv180006r12","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1097\/DSS.0000000000000910","article-title":"A comparison of Mohs micrographic surgery and wide local excision for treatment of dermatofibrosarcoma protuberans with long-term follow-up: the Mayo Clinic experience.","volume":"43","author":"Lowe","year":"2017","journal-title":"Dermatol Surg"},{"issue":"1","key":"drv180006r13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/(ISSN)1098-2264","article-title":"Genetics of dermatofibrosarcoma protuberans family of tumors: from ring chromosomes to tyrosine kinase inhibitor treatment.","volume":"37","author":"Sirvent","year":"2003","journal-title":"Genes Chromosomes Cancer"},{"issue":"1","key":"drv180006r14","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1038\/ng0197-95","article-title":"Deregulation of the platelet-derived growth factor B-chain gene via fusion with collagen gene COL1A1 in dermatofibrosarcoma protuberans and giant-cell fibroblastoma.","volume":"15","author":"Simon","year":"1997","journal-title":"Nat Genet"},{"issue":"17","key":"drv180006r15","doi-asserted-by":"publisher","first-page":"3586","DOI":"10.1200\/JCO.2002.01.027","article-title":"Molecular targeting of platelet-derived growth factor B by imatinib mesylate in a patient with metastatic dermatofibrosarcoma protuberans.","volume":"20","author":"Rubin","year":"2002","journal-title":"J Clin Oncol"},{"key":"drv180006r16","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1186\/s13256-015-0561-4","article-title":"Orbital dermatofibrosarcoma protuberans with intracranial extension preceded by recurrent leiomyoma of the orbit: a case report.","volume":"9","author":"Bashir","year":"2015","journal-title":"J Med Case Rep"},{"issue":"6","key":"drv180006r17","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1016\/j.jdcr.2017.06.019","article-title":"Recurrent dermatofibrosarcoma protuberans treated with neoadjuvant imatinib mesylate followed by Mohs micrographic surgery.","volume":"3","author":"Fontecilla","year":"2017","journal-title":"JAAD Case Rep"},{"issue":"10","key":"drv180006r18","doi-asserted-by":"publisher","first-page":"1772","DOI":"10.1200\/JCO.2009.25.7899","article-title":"Imatinib mesylate in advanced dermatofibrosarcoma protuberans: pooled analysis of two phase II clinical trials.","volume":"28","author":"Rutkowski","year":"2010","journal-title":"J Clin Oncol"},{"issue":"17","key":"drv180006r20","doi-asserted-by":"publisher","first-page":"2604","DOI":"10.1016\/j.ejca.2015.06.108","article-title":"Diagnosis and treatment of dermatofibrosarcoma protuberans: European consensus-based interdisciplinary guideline.","volume":"51","author":"Saiag","year":"2015","journal-title":"Eur J Cancer"},{"key":"drv180006r21","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1186\/s13643-016-0259-8","article-title":"Evaluation of the Cochrane tool for assessing risk of bias in randomized clinical trials: overview of published comments and analysis of user practice in Cochrane and non-Cochrane reviews.","volume":"5","author":"J\u00f8rgensen","year":"2016","journal-title":"Syst Rev"},{"key":"drv180006r22","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/1471-2288-5-13","article-title":"Estimating the mean and variance from the median, range, and the size of a sample.","volume":"5","author":"Hozo","year":"2005","journal-title":"BMC Med Res Methodol"},{"issue":"4","key":"drv180006r23","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1200\/JCO.2005.07.088","article-title":"Molecular and clinical analysis of locally advanced dermatofibrosarcoma protuberans treated with imatinib: Imatinib Target Exploration Consortium Study B2225.","volume":"23","author":"McArthur","year":"2005","journal-title":"J Clin Oncol"},{"issue":"7","key":"drv180006r24","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1001\/archdermatol.2009.140","article-title":"Neoadjuvant imatinib therapy for dermatofibrosarcoma protuberans.","volume":"145","author":"Han","year":"2009","journal-title":"Arch Dermatol"},{"issue":"2","key":"drv180006r25","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1158\/1078-0432.CCR-13-1411","article-title":"Neoadjuvant imatinib in advanced primary or locally recurrent dermatofibrosarcoma protuberans: a multicenter phase II DeCOG trial with long-term follow-up.","volume":"20","author":"Ugurel","year":"2014","journal-title":"Clin Cancer Res"},{"issue":"9","key":"drv180006r26","doi-asserted-by":"publisher","first-page":"2717","DOI":"10.1158\/1078-0432.CCR-07-4575","article-title":"Phase II, open-label study evaluating the activity of imatinib in treating life-threatening malignancies known to be associated with imatinib-sensitive tyrosine kinases.","volume":"14","author":"Heinrich","year":"2008","journal-title":"Clin Cancer Res"},{"issue":"17","key":"drv180006r27","doi-asserted-by":"publisher","first-page":"e773","DOI":"10.1097\/MD.0000000000000773","article-title":"Target therapy of unresectable or metastatic dermatofibrosarcoma protuberans with imatinib mesylate: an analysis on 22 Chinese patients.","volume":"94","author":"Wang","year":"2015","journal-title":"Medicine (Baltimore)"},{"issue":"4","key":"drv180006r28","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1158\/1078-0432.CCR-15-1243","article-title":"Efficacy and biological activity of imatinib in metastatic dermatofibrosarcoma protuberans (DFSP).","volume":"22","author":"Stacchiotti","year":"2016","journal-title":"Clin Cancer Res"},{"issue":"12","key":"drv180006r29","doi-asserted-by":"publisher","first-page":"3288","DOI":"10.1158\/1078-0432.CCR-09-3401","article-title":"Imatinib mesylate as a preoperative therapy in dermatofibrosarcoma: results of a multicenter phase II study on 25 patients.","volume":"16","author":"K\u00e9rob","year":"2010","journal-title":"Clin Cancer Res"},{"issue":"2","key":"drv180006r30","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1016\/j.jid.2016.06.634","article-title":"Adaptive immunity in fibrosarcomatous dermatofibrosarcoma protuberans and response to imatinib treatment.","volume":"137","author":"Tazzari","year":"2017","journal-title":"J Invest Dermatol"},{"issue":"2","key":"drv180006r31","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1016\/j.jid.2016.10.027","article-title":"Imatinib in dermatofibrosarcoma: targeted therapy or immunotherapy?","volume":"137","author":"Ugurel","year":"2017","journal-title":"J Invest Dermatol"},{"issue":"4","key":"drv180006r32","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1097\/DAD.0000000000000746","article-title":"Dermatofibrosarcoma protuberans-like tumor with COL1A1 copy number gain in the absence of t(17;22).","volume":"39","author":"Saab","year":"2017","journal-title":"Am J Dermatopathol"},{"issue":"9291","key":"drv180006r33","doi-asserted-by":"publisher","first-page":"1421","DOI":"10.1016\/S0140-6736(01)06535-7","article-title":"Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I study.","volume":"358","author":"van Oosterom","year":"2001","journal-title":"Lancet"},{"issue":"9440","key":"drv180006r34","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1016\/S0140-6736(04)17098-0","article-title":"Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial.","volume":"364","author":"Verweij","year":"2004","journal-title":"Lancet"},{"issue":"7","key":"drv180006r35","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1016\/j.ad.2013.01.009","article-title":"Adverse skin effects of imatinib, a tyrosine kinase inhibitor.","volume":"105","author":"Pretel-Irazabal","year":"2014","journal-title":"Actas Dermosifiliogr"},{"issue":"12","key":"drv180006r36","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1016\/j.clml.2017.07.005","article-title":"Cutaneous adverse events of targeted therapies for hematolymphoid malignancies.","volume":"17","author":"Ransohoff","year":"2017","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"6","key":"drv180006r37","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.1038\/leu.2009.38","article-title":"Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia.","volume":"23","author":"Hochhaus","year":"2009","journal-title":"Leukemia"},{"issue":"23","key":"drv180006r38","doi-asserted-by":"publisher","first-page":"2408","DOI":"10.1056\/NEJMoa062867","article-title":"Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia.","volume":"355","author":"Druker","year":"2006","journal-title":"N Engl J Med"},{"key":"drv180006r19","unstructured":"National Comprehensive Cancer Network. Dermatofibrosarcoma protuberans (Version 1.2018). 2017; https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/dfsp.pdf. Accessed October 27, 2017."}],"container-title":["JAMA Dermatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/\/jamadermatology\/article-pdf\/155\/3\/361\/17393183\/jamadermatology_navarretedechent_2019_rv_180006.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,3,13]],"date-time":"2019-03-13T12:33:58Z","timestamp":1552480438000},"score":1,"resource":{"primary":{"URL":"http:\/\/archderm.jamanetwork.com\/article.aspx?doi=10.1001\/jamadermatol.2018.4940"}},"subtitle":["A Systematic Review"],"short-title":[],"issued":{"date-parts":[[2019,3,1]]},"references-count":38,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019,3,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamadermatol.2018.4940","relation":{},"ISSN":["2168-6068"],"issn-type":[{"value":"2168-6068","type":"print"}],"subject":[],"published":{"date-parts":[[2019,3,1]]}}}